Details of the Drug

General Information of Drug (ID: DMI2QPE)

Drug Name

Didanosine

Synonyms

didanosine; 69655-05-6; DIDEOXYINOSINE; Videx; Videx EC; Inosine, 2',3'-dideoxy-; ddIno; Didanosina; Didanosinum; DDI; BMY-40900; UNII-K3GDH6OH08; K3GDH6OH08; Didanosinum [INN-Latin]; Didanosina [INN-Spanish]; CHEBI:490877; 9-(2,3-Dideoxy-beta-D-ribofuranosyl)-6-oxopurine; NSC 612049; 9-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,9-dihydro-6H-purin-6-one; 9-[(2R,5R)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-2-YL]-1,9-DIHYDRO-6H-PURIN-6-ONE; NCGC00159514-02; NCGC00090691-03; DRG-0016; BMY 40900; DSSTox_CID_2927

Indication

Disease Entry	ICD 11	Status	REF
Human immunodeficiency virus infection	1C62	Approved	[1], [2]

Therapeutic Class

Anti-HIV Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

236.23

Topological Polar Surface Area (xlogp)

-1.2

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [3]
Clearance: The drug present in the plasma can be removed from the body at the rate of 11 mL/min/kg [4]
Elimination: 55% of drug is excreted from urine in the unchanged form [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 30 minutes (in plasma), and more than 12 hours (in intracellular environment) [4]
Metabolism: The drug is metabolized via the hepatic [5]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 24.19 micromolar/kg/day [6]
Unbound Fraction: The unbound fraction of drug in plasma is 0.95% [4]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.77 L/kg [4]
Water Solubility: The ability of drug to dissolve in water is measured as 27.3 mg/mL [3]

Chemical Identifiers

Formula: C10H12N4O3
IUPAC Name: 9-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]-1H-purin-6-one
Canonical SMILES: C1C[C@@H](O[C@@H]1CO)N2C=NC3=C2N=CNC3=O
InChI: InChI=1S/C10H12N4O3/c15-3-6-1-2-7(17-6)14-5-13-8-9(14)11-4-12-10(8)16/h4-7,15H,1-3H2,(H,11,12,16)/t6-,7+/m0/s1
InChIKey: BXZVVICBKDXVGW-NKWVEPMBSA-N

Cross-matching ID

PubChem CID: 135398739
ChEBI ID: CHEBI:490877
CAS Number: 69655-05-6
DrugBank ID: DB00900
TTD ID: D06FDR
VARIDT ID: DR01175
ACDINA ID: D00195

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human immunodeficiency virus Reverse transcriptase (HIV RT)	TT84ETX	POL_HV1B1	Inhibitor	[7]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Concentrative nucleoside transporter 2 (SLC28A2)	DT82KPY	S28A2_HUMAN	Substrate	[8]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Didanosine

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Disease	REF
Cobicistat	DM6L4H2	Moderate	Decreased metabolism of Didanosine caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Elvitegravir	DMG9B1U	Moderate	Decreased absorption of Didanosine due to formation of complexes caused by Elvitegravir.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Zalcitabine	DMH7MUV	Moderate	Increased risk of peripheral neuropathy by the combination of Didanosine and Zalcitabine.	Human immunodeficiency virus disease [1C60-1C62]	[21]
Lopinavir	DMITQS0	Moderate	Decreased absorption of Didanosine due to formation of complexes caused by Lopinavir.	Human immunodeficiency virus disease [1C60-1C62]	[22]
Darunavir	DMN3GCH	Moderate	Altered absorption of Didanosine caused by Darunavir.	Human immunodeficiency virus disease [1C60-1C62]	[23]
Atazanavir	DMSYRBX	Moderate	Decreased absorption of Didanosine due to altered gastric pH caused by Atazanavir.	Human immunodeficiency virus disease [1C60-1C62]	[20]
-----------


⏷ Show the Full List of 6 DDI Information of This Drug

Coadministration of a Drug Treating the Disease Different from Didanosine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Remdesivir	DMBFZ6L	Moderate	Increased risk of hepatotoxicity by the combination of Didanosine and Remdesivir.	1D6YCoronavirus Disease 2019 [1D6YCoronavirus Disease 2019]	[20]
Cefuroxime	DMSIMD8	Moderate	Decreased absorption of Didanosine due to altered gastric pH caused by Cefuroxime.	Acute bronchitis [CA42]	[24]
Bedaquiline	DM3906J	Moderate	Increased risk of hepatotoxicity by the combination of Didanosine and Bedaquiline.	Antimicrobial drug resistance [MG50-MG52]	[25]
Lisdexamfetamine	DM6W8V5	Moderate	Decreased absorption of Didanosine due to altered gastric pH caused by Lisdexamfetamine.	Attention deficit hyperactivity disorder [6A05]	[26]
Ofloxacin	DM0VQN3	Moderate	Decreased absorption of Didanosine due to formation of complexes caused by Ofloxacin.	Bacterial infection [1A00-1C4Z]	[27]
Sparfloxacin	DMB4HCT	Moderate	Decreased absorption of Didanosine due to formation of complexes caused by Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[28]
Gemifloxacin	DMHT34O	Moderate	Decreased absorption of Didanosine due to formation of complexes caused by Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[29]
Norfloxacin	DMIZ6W2	Moderate	Decreased absorption of Didanosine due to formation of complexes caused by Norfloxacin.	Bacterial infection [1A00-1C4Z]	[30]
ABT-492	DMJFD2I	Moderate	Decreased absorption of Didanosine due to formation of complexes caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[29]
Cefpodoxime	DMJUNY5	Moderate	Decreased absorption of Didanosine due to altered gastric pH caused by Cefpodoxime.	Bacterial infection [1A00-1C4Z]	[24]
Bacampicillin	DMP54C7	Moderate	Decreased absorption of Didanosine due to altered gastric pH caused by Bacampicillin.	Bacterial infection [1A00-1C4Z]	[24]
Levofloxacin	DMS60RB	Moderate	Decreased absorption of Didanosine due to formation of complexes caused by Levofloxacin.	Bacterial infection [1A00-1C4Z]	[31]
Cefditoren	DMSUVM1	Moderate	Decreased absorption of Didanosine due to altered gastric pH caused by Cefditoren.	Bacterial infection [1A00-1C4Z]	[32]
Lomefloxacin	DMVRH9C	Moderate	Decreased absorption of Didanosine due to formation of complexes caused by Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[29]
Etidronic acid	DM1XHYJ	Moderate	Decreased absorption of Didanosine due to formation of complexes caused by Etidronic acid.	Bone paget disease [FB85]	[33]
Pexidartinib	DMS2J0Z	Major	Increased risk of hepatotoxicity by the combination of Didanosine and Pexidartinib.	Bone/articular cartilage neoplasm [2F7B]	[34]
Mycophenolic acid	DMU65NK	Moderate	Decreased absorption of Didanosine due to altered gastric pH caused by Mycophenolic acid.	Crohn disease [DD70]	[35]
Clonazepam	DMTO13J	Minor	Altered absorption of Didanosine due to GI dynamics variation caused by Clonazepam.	Epilepsy/seizure [8A61-8A6Z]	[36]
Itraconazole	DMCR1MV	Moderate	Decreased absorption of Didanosine due to altered gastric pH caused by Itraconazole.	Fungal infection [1F29-1F2F]	[37]
Ketoconazole	DMPZI3Q	Moderate	Decreased absorption of Didanosine due to altered gastric pH caused by Ketoconazole.	Fungal infection [1F29-1F2F]	[37]
Rifampin	DMA8J1G	Moderate	Decreased absorption of Didanosine due to altered gastric pH caused by Rifampin.	HIV-infected patients with tuberculosis [1B10-1B14]	[38]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of peripheral neuropathy by the combination of Didanosine and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[39]
Mipomersen	DMGSRN1	Major	Increased risk of hepatotoxicity by the combination of Didanosine and Mipomersen.	Hyper-lipoproteinaemia [5C80]	[40]
Teriflunomide	DMQ2FKJ	Major	Increased risk of hepatotoxicity by the combination of Didanosine and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[22]
BMS-201038	DMQTAGO	Major	Increased risk of hepatotoxicity by the combination of Didanosine and BMS-201038.	Hyper-lipoproteinaemia [5C80]	[41]
Captopril	DM458UM	Minor	Decreased absorption of Didanosine due to altered gastric pH caused by Captopril.	Hypertension [BA00-BA04]	[42]
Quazepam	DMY4D87	Minor	Altered absorption of Didanosine due to GI dynamics variation caused by Quazepam.	Insomnia [7A00-7A0Z]	[36]
Estazolam	DMZGXUM	Minor	Altered absorption of Didanosine due to GI dynamics variation caused by Estazolam.	Insomnia [7A00-7A0Z]	[36]
Calaspargase pegol	DMQZBXI	Moderate	Increased risk of hepatotoxicity by the combination of Didanosine and Calaspargase pegol.	Malignant haematopoietic neoplasm [2B33]	[43]
Idelalisib	DM602WT	Moderate	Increased risk of hepatotoxicity by the combination of Didanosine and Idelalisib.	Mature B-cell leukaemia [2A82]	[44]
Thalidomide	DM70BU5	Moderate	Increased risk of peripheral neuropathy by the combination of Didanosine and Thalidomide.	Multiple myeloma [2A83]	[21]
Dasatinib	DMJV2EK	Moderate	Decreased absorption of Didanosine due to altered gastric pH caused by Dasatinib.	Myeloproliferative neoplasm [2A20]	[45]
Dextroamphetamine	DMMIHVP	Moderate	Decreased absorption of Didanosine due to altered gastric pH caused by Dextroamphetamine.	Narcolepsy [7A20]	[26]
Orlistat	DMRJSP8	Moderate	Altered absorption of Didanosine caused by Orlistat.	Obesity [5B80-5B81]	[46]
Methamphetamine	DMPM4SK	Moderate	Decreased absorption of Didanosine due to altered gastric pH caused by Methamphetamine.	Pain [MG30-MG3Z]	[47]
Gatifloxacin	DMSL679	Moderate	Decreased absorption of Didanosine due to formation of complexes caused by Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[29]
Leflunomide	DMR8ONJ	Major	Increased risk of hepatotoxicity by the combination of Didanosine and Leflunomide.	Rheumatoid arthritis [FA20]	[22]
Trabectedin	DMG3Y89	Moderate	Increased risk of hepatotoxicity by the combination of Didanosine and Trabectedin.	Solid tumour/cancer [2A00-2F9Z]	[48]
Deferiprone	DMS2M7O	Moderate	Decreased absorption of Didanosine due to formation of complexes caused by Deferiprone.	Thalassaemia [3A50]	[49]
Eltrombopag	DMOGFIX	Moderate	Decreased absorption of Didanosine due to formation of complexes caused by Eltrombopag.	Thrombocytopenia [3B64]	[48]
-----------


⏷ Show the Full List of 40 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
Aspartame	E00402	134601	Flavoring agent
Calcium carbonate	E00198	10112	Binding agent; Buffering agent; Diluent; Opacifying agent
D&C red no. 28	E00491	6097185	Colorant
D&C red no. 33	E00261	19116	Colorant
Diethyl phthalate	E00135	6781	Plasticizing agent; Solvent
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Sodium lauryl sulfate	E00464	3423265	Emulsifying agent; Modified-release agent; Penetration agent; Solubilizing agent; Surfactant; lubricant
Sunset yellow FCF	E00255	17730	Colorant
Ammonia	E00007	222	Alkalizing agent
Carboxymethylcellulose sodium	E00621	Not Available	Adsorbent; Binding agent; Disintegrant; Emulsifying agent; Suspending agent; Viscosity-controlling agent
Carmellose sodium	E00625	Not Available	Disintegrant
Crospovidone	E00626	Not Available	Disintegrant
Eisenoxyd	E00585	56841934	Colorant
Ferric hydroxide oxide yellow	E00539	23320441	Colorant
Ferrosoferric oxide	E00231	14789	Colorant
Hexahydric alcohol	E00083	5780	Diluent; Flavoring agent; Humectant; Plasticizing agent
Hypromellose	E00634	Not Available	Coating agent
Magnesium hydroxide	E00374	73981	Adsorbent; Buffering agent
Magnesium stearate	E00208	11177	lubricant
Potassium hydroxide	E00233	14797	Alkalizing agent
Propylene glycol	E00040	1030	Antimicrobial preservative; Humectant; Plasticizing agent; Solvent
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Sodium citrate dihydrate	E00369	71474	Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Sodium hydroxide	E00234	14798	Alkalizing agent
Talc	E00520	16211421	Anticaking agent; Diluent; Glidant; lubricant
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Triethyl citrate	E00128	6506	Plasticizing agent; Solvent
--------------------


⏷ Show the Full List of 31 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Didanosine 200 mg capsule	200 mg	Delayed Release Oral Capsule	Oral
Didanosine 250 mg capsule	250 mg	Delayed Release Oral Capsule	Oral
Didanosine 400 mg capsule	400 mg	Delayed Release Oral Capsule	Oral
Didanosine 125 mg capsule	125 mg	Delayed Release Oral Capsule	Oral
Didanosine 100 mg tablet	100 mg	Chewable Tablet	Oral
Didanosine 150 mg tablet	150 mg	Chewable Tablet	Oral
Didanosine 200 mg tablet	200 mg	Chewable Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4833).
2	Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3	BDDCS applied to over 900 drugs
4	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5	FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
6	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
7	The effect of individual antiretroviral drugs on body composition in HIV-infected persons initiating highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2009 Jul 1;51(3):298-304.
8	Clinical Nephrotoxins: Renal Injury from Drugs and Chemicals.
9	PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA2040)
10	Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278.
11	Identification and functional analysis of variants in the human concentrative nucleoside transporter 2, hCNT2 (SLC28A2) in Chinese, Malays and Indians. Pharmacogenet Genomics. 2007 Sep;17(9):783-6.
12	Transport of ribavirin across the rat and human placental barrier: Roles of nucleoside and ATP-binding cassette drug efflux transporters. Biochem Pharmacol. 2019 May;163:60-70.
13	Antiviral drugs in current clinical use. J Clin Virol. 2004 Jun;30(2):115-33.
14	HIV-1 reverse transcriptase complex with DNA and nevirapine reveals non-nucleoside inhibition mechanism.Nat Struct Mol Biol.2012 Jan 22;19(2):253-9.
15	A peptide inhibitor of HIV-1 reverse transcriptase using alpha,beta-dehydro residues: a structure-based computer model. J Biomol Struct Dyn. 1998 Oct;16(2):347-54.
16	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
17	Quadruple nucleos(t)ide reverse transcriptase inhibitors-only regimen of tenofovir plus zidovudine/lamivudine/abacavir in heavily pre-treated HIV-1 infected patients: salvage therapy or backbone only Curr HIV Res. 2009 May;7(3):320-6.
18	Emerging antiviral drugs. Expert Opin Emerg Drugs. 2008 Sep;13(3):393-416.
19	2008 FDA drug approvals. Nat Rev Drug Discov. 2009 Feb;8(2):93-6.
20	Cerner Multum, Inc. "Australian Product Information.".
21	Argov Z, Mastaglia FL "Drug-induced peripheral neuropathies." Br Med J 1 (1979): 663-6. [PMID: 219931]
22	Canadian Pharmacists Association.
23	Product Information. Prezista (darunavir). Ortho Biotech Inc, Bridgewater, NJ.
24	Honig PK, Gillespie BK "Clinical significance of pharmacokinetic drug interactions with over-the-counter (OTC) drugs." Clin Pharmacokinet 35 (1998): 167-71. [PMID: 9784931]
25	Product Information. Sirturo (bedaquiline). Janssen Pharmaceuticals, Titusville, NJ.
26	Product Information. Adderall (amphetamine-dextroamphetamine) Shire Richwood Pharmaceutical Company, Florence, KY.
27	Akerele JO, Okhamafe AO "Influence of oral co-administered metallic drugs on ofloxacin pharmacokinetics." J Antimicrob Chemother 28 (1991): 87-94. [PMID: 1663108]
28	Johnson RD, Dorr MB, Talbot GH, Caille G "Effect of Maalox on the oral absorption of sparfloxacin." Clin Ther 20 (1998): 1149-58. [PMID: 9916608]
29	Deppermann KM, Lode H "Fluoroquinolones: interaction profile during enteral absorption." Drugs 45 Suppl 3 (1993): 65-72. [PMID: 7689454]
30	Campbell NR, Kara M, Hasinoff BB, Haddara WM, McKay DW "Norfloxacin interaction with antacids and minerals." Br J Clin Pharmacol 33 (1992): 115-6. [PMID: 1540482]
31	Davis R, Bryson HM "Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy [published erratum appears in Drugs 1994 Jul 48(1):132]." Drugs 47 (1994): 677-700. [PMID: 7516863]
32	Product Information. Spectracef (cefditoren). TAP Pharmaceuticals Inc, Deerfield, IL.
33	Product Information. Boniva (ibandronate). Roche Laboratories, Nutley, NJ.
34	Product Information. Turalio (pexidartinib). Daiichi Sankyo, Inc., Parsippany, NJ.
35	Bullingham R, Shah J, Goldblum R, Schiff M "Effects of food and antacid on the pharmacokinetics of single doses of mycophenolate mofetil in rheumatoid arthritis patients." Br J Clin Pharmacol 41 (1996): 513-6. [PMID: 8799515]
36	Chun AH, Carrigan PJ, Hoffman DJ, Kershner RP, Stuart JD "Effect of antacids on absorption of clorazepate." Clin Pharmacol Ther 22 (1977): 329-35. [PMID: 19188]
37	May DB, Drew RH, Yedinak KC, Bartlett JA "Effect of simultaneous didanosine administration on itraconazole absorption in healthy volunteers." Pharmacotherapy 14 (1994): 509-13. [PMID: 7997384]
38	Product Information. Rifadin (rifampin). Hoechst Marion-Roussel Inc, Kansas City, MO.
39	Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.
40	Product Information. Kynamro (mipomersen). Genzyme Corporation, Cambridge, MA.
41	Product Information. Juxtapid (lomitapide). Aegerion Pharmaceuticals Inc, Cambridge, MA.
42	Mantyla R, Mannisto PT, Vuorela A, Sundberg S, Ottoila P "Impairment of captopril bioavailability by concomitant food and antacid intake." Int J Clin Pharmacol Ther Toxicol 22 (1984): 626-9. [PMID: 6389377]
43	Al-Nawakil C, Willems L, Mauprivez C, et.al "Successful treatment of l-asparaginase-induced severe acute hepatotoxicity using mitochondrial cofactors." Leuk Lymphoma 55 (2014): 1670-4. [PMID: 24090500]
44	Product Information. Zydelig (idelalisib). Gilead Sciences, Foster City, CA.
45	Product Information. Sprycel (dasatinib). Bristol-Myers Squibb, Princeton, NJ.
46	MHRA. Medicines and Healthcare Products Regulatory Agency "Orlistat: theoretical interaction with antiretroviral HIV medicines.".
47	Mendelson J, Jones RT, Upton R, Jacob P 3rd "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther 57 (1995): 559-68. [PMID: 7768079]
48	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
49	Product Information. Ferriprox (deferiprone). ApoPharma USA Inc, Rockville, MD.